Bu G, Rennke S
Edward Mallinkrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Biol Chem. 1996 Sep 6;271(36):22218-24. doi: 10.1074/jbc.271.36.22218.
The 39-kDa receptor-associated protein (RAP) is a receptor antagonist that inhibits ligand interactions with the receptors that belong to the low density lipoprotein receptor gene family. Our previous studies have demonstrated that RAP interacts with the low density lipoprotein receptor-related protein (LRP) within the endoplasmic reticulum and prevents premature interaction of ligands with the receptor. To analyze whether RAP is also involved in the folding of LRP during receptor biosynthesis, we generated anchor-free, soluble minireceptors that represent each of the four putative ligand-binding domains of LRP (SLRP1, -2, -3, and -4, corresponding to the clusters with 2, 8, 10, and 11 cysteine-rich complement-type repeats, respectively). When these SLRPs were overexpressed by cell transfection, only SLRP1 was secreted. Little or no secretion was observed for SLRP2, -3, and -4. However, when RAP cDNA was cotransfected with SLRP2, -3, and -4 cDNAs, each of these SLRPs was secreted. The cellular retention of SLRPs in the absence of RAP coexpression appeared to be a result of the formation of SDS-resistant, oligomeric aggregates observed under nonreducing conditions. Such oligomers of the SLRPs likely resulted from formation of intermolecular disulfide bonds since they were reduced to monomers when analyzed under reducing conditions. The oligomers were formed not only among molecules of a given SLRP, but also between different SLRPs. The role of RAP in the process of LRP folding was shown by the reduction in aggregated SLRP oligomers upon RAP coexpression. A similar role of RAP in preventing the aggregation of newly synthesized receptor was also observed using membrane-containing minireceptor of LRP. Coimmunoprecipitation and ligand binding studies demonstrated that RAP binds avidly to SLRP2, -3, and -4, but not to SLRP1. These results suggest that these interactions may be important for proper folding of LRP by ensuring the formation of proper intradomain, but not intermolecular or interdomain, disulfide bonds. Thus, our results strongly suggest that, in addition to the prevention of premature binding of ligands to LRP, RAP also plays an important role in receptor folding.
39 kDa受体相关蛋白(RAP)是一种受体拮抗剂,可抑制配体与属于低密度脂蛋白受体基因家族的受体之间的相互作用。我们之前的研究表明,RAP在内质网中与低密度脂蛋白受体相关蛋白(LRP)相互作用,并防止配体与该受体过早发生相互作用。为了分析RAP在受体生物合成过程中是否也参与LRP的折叠,我们构建了无锚定的可溶性微型受体,它们分别代表LRP的四个假定配体结合结构域(SLRP1、-2、-3和-4,分别对应于具有2、8、10和11个富含半胱氨酸的补体样重复序列的簇)。当通过细胞转染使这些SLRP过表达时,只有SLRP1被分泌出来。未观察到SLRP2、-3和-4有分泌或仅有少量分泌。然而,当RAP cDNA与SLRP2、-3和-4 cDNA共转染时,这些SLRP均被分泌。在没有RAP共表达的情况下,SLRP在细胞内的滞留似乎是由于在非还原条件下观察到形成了抗SDS的寡聚聚集体。这些SLRP的寡聚体可能是由于分子间二硫键的形成所致,因为在还原条件下分析时它们会还原为单体。寡聚体不仅在给定的SLRP分子之间形成,也在不同的SLRP之间形成。RAP共表达后聚集的SLRP寡聚体减少,这表明RAP在LRP折叠过程中发挥了作用。使用含膜的LRP微型受体也观察到RAP在防止新合成受体聚集方面具有类似作用。免疫共沉淀和配体结合研究表明,RAP与SLRP2、-3和-4紧密结合,但不与SLRP1结合。这些结果表明,这些相互作用可能通过确保形成合适的结构域内而非分子间或结构域间二硫键,对LRP的正确折叠很重要。因此,我们的结果有力地表明,除了防止配体与LRP过早结合外,RAP在受体折叠中也起着重要作用。